COVID-19 infection. COVID-19, virus identified
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Provide written informed consent Subjects age > 18 years at the time of signing the Informed Consent Form. Male or Female Must have a clinical diagnosis of COVID-19, with at least one clinical symptom (e.g., fever =38°C, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (RT-PCR) testing or equivalent. Individuals with severe COVID-19 symptoms according to Berlin Criteria Hospitalized patients and on Mechanical Ventilation Patients requiring FiO2 of 0.5 or more and a PEEP of 5 mmHg or more Ability to provide informed consent or an authorized representative can sign the informed consent
Exclusion criteria
Exclusion criteria: Pregnant females Patients with HIV infection. Patients with active tuberculosis or a history of treatment for pulmonary tuberculosis Patients with a CrCl of less than 30 ml/minute Patients with heart disease and an ejection fraction of 30% or less Patients with advanced liver disease Patients allergic to methylprednisolone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In-hospital mortality. Timepoint: 28 days. Method of measurement: Pre-designed Performa. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of hospital stay. Timepoint: 28 days. Method of measurement: Predesigned performa.;Improvement in lung mechanics. Timepoint: 28 days. Method of measurement: predesigned performa.;Improvement in inflammatory markers. Timepoint: 28 days. Method of measurement: predesigned performa.;Incidence of secondary infections. Timepoint: 28 days. Method of measurement: predesigned performa. | — |
Countries
Pakistan
Contacts
Pakistan Institute of Medical Sciences